Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and rearrangement.
作者信息
Yan Yiru, Qu Shiqiang, Liu Jinqin, Li Chengwen, Yan Xiao, Xu Zefeng, Qin Tiejun, Jia Yujiao, Pan Lijuan, Gao Qingyan, Jiao Meng, Li Bing, Gale Robert Peter, Xiao Zhijian
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China.
Tianjin Institutes of Health Science, Tianjin, P.R. China.
出版信息
Leuk Lymphoma. 2023 Sep;64(9):1605-1610. doi: 10.1080/10428194.2023.2226277. Epub 2023 Jun 24.
Abstract
摘要
相似文献
1
Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and rearrangement.奥雷巴替尼用于治疗与嗜酸性粒细胞增多和重排相关的髓系/淋系肿瘤。
Leuk Lymphoma. 2023 Sep;64(9):1605-1610. doi: 10.1080/10428194.2023.2226277. Epub 2023 Jun 24.
2
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.用FGFR1抑制剂治疗伴有FGFR1重排的髓系/淋系肿瘤。
Ann Oncol. 2018 Aug 1;29(8):1880-1882. doi: 10.1093/annonc/mdy173.
3
Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report.伴有嗜酸性粒细胞增多和 BCR/FGFR1 重排的髓系/淋巴肿瘤，伴向皮质 T 淋巴母细胞淋巴瘤和红系前体细胞转化：一例报告。
J Med Case Rep. 2023 Jan 26;17(1):39. doi: 10.1186/s13256-022-03722-y.
4
[Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1].伴有嗜酸性粒细胞增多及血小板衍生生长因子受体α（PDGFRA）、血小板衍生生长因子受体β（PDGFRB）或成纤维细胞生长因子受体1（FGFR1）异常的髓系和淋巴系肿瘤
Zhonghua Bing Li Xue Za Zhi. 2012 Nov;41(11):779-83. doi: 10.3760/cma.j.issn.0529-5807.2012.11.018.
5
Myeloid/lymphoid neoplasm associated with eosinophilia and concurrent rearrangement of PDGFRA and FGFR1: A very rare pediatric case.与嗜酸性粒细胞增多及血小板衍生生长因子受体α（PDGFRA）和成纤维细胞生长因子受体1（FGFR1）同时重排相关的髓系/淋系肿瘤：1例极罕见的儿科病例
Pediatr Blood Cancer. 2023 Oct;70(10):e30507. doi: 10.1002/pbc.30507. Epub 2023 Jun 19.
6
Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
Blood. 2021 Sep 9;138(10):912. doi: 10.1182/blood.2021012168.
7
Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature.伴有FGFR1异常、呈现三系原始细胞及RUNX1重排的髓系和淋系肿瘤：一例报告并文献复习
Am J Clin Pathol. 2015 May;143(5):738-48. doi: 10.1309/AJCPUD6W1JLQQMNA.
8
Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission.
Pediatr Blood Cancer. 2024 Jan;71(1):e30721. doi: 10.1002/pbc.30721. Epub 2023 Oct 13.
9
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
Am J Hematol. 2023 Dec;98(12):1959-1962. doi: 10.1002/ajh.27026. Epub 2023 Jul 12.
10
Myeloid/lymphoid neoplasm with a novel cryptic rearrangement presenting as de novo acute leukemias.
Leuk Lymphoma. 2023 Dec;64(14):2338-2342. doi: 10.1080/10428194.2023.2262640. Epub 2023 Dec 25.
引用本文的文献
1
[Guideline of the diagnosis and treatment of eosinophilic disorders (2024)].[嗜酸性粒细胞相关疾病的诊断和治疗指南（2024年）]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):1-7. doi: 10.3760/cma.j.cn121090-20231222-00334.
2
Hematological Neoplasms with Eosinophilia.伴有嗜酸性粒细胞增多的血液系统肿瘤
Cancers (Basel). 2024 Jan 12;16(2):337. doi: 10.3390/cancers16020337.
Zotero 插件